Korro Bio Raises $85M, Extends Cash Runway to H2 2028; Advances RNA Editing Programs
Korro Bio closed Q1 2026 with $157.1M in cash and securities, up from $85.2M, after an $85M oversubscribed private placement extending its cash runway into H2 2028. The company advanced its lead RNA editing program toward an H2 2026 regulatory filing and achieved over 90% editing in its AATD candidate.
1. Q1 Financial Performance
Korro Bio reported cash, cash equivalents and marketable securities of $157.1M as of March 31, 2026, versus $85.2M at December 31, 2025. Collaboration revenue dropped to zero from $2.6M due to a paused agreement, while R&D expenses decreased to $12.9M and G&A expenses totaled $7.5M.
2. $85M Private Placement
The company executed an oversubscribed $85M private placement led by Venrock Healthcare Capital Partners, boosting its balance sheet and expected to fund operations and clinical programs into the second half of 2028.
3. Pipeline Progress
Korro highlighted its OPERA® RNA editing platform, with KRRO-121 on track for an H2 2026 regulatory filing as a potential treatment for hyperammonemia, and achieved over 90% in vivo RNA editing in its GalNAc-conjugated AATD program.
4. Upcoming Milestones
The company plans to announce a development candidate for its AATD program in Q2 2026, nominate a third GalNAc-conjugated candidate in H2 2026, and present preclinical data at the ASGCT annual meeting in May 2026.